Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Future Oncology

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LNL. NayakCGC. GrommesCPCharles Psoinos

Discussion

Loading...

Member takes

Overview

Randomized trial compares tirabrutinib to rituximab and temozolomide in relapsed/refractory PCNSL, suggesting new treatment options.

Key Points

  • This study aims to evaluate the efficacy and safety of tirabrutinib compared to rituximab and temozolomide in treating relapsed/refractory primary central nervous system lymphoma.
  • Phase III, multiregional, open-label, randomized study
  • Primary endpoint is progression-free survival assessed by blinded independent review committee
  • Trial registered at clinicaltrials.gov (NCT07104032)
  • The primary endpoint measure is progression-free survival according to IPCG criteria.
  • Key secondary endpoints include overall response rate and overall survival based on BIRC assessments.
  • Safety will be evaluated through treatment-emergent adverse events.

Cite This Study

Nayak et al. (2026) studied this question.

synapsesocial.com/papers/6a3632d2db0793dc1a539475https://doi.org/10.1080/14796694.2026.2683574
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma2025
  2. 2A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)2026
  3. 3P17.14.B A RETROSPECTIVE STUDY OF THE BTK-INHIBITOR TIRABRUTINIB FOR THE TREATMENT OF RECURRENT/REFRACTORY PRIMARY CNS LYMPHOMA2025
  4. 4Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL)2026 · 2 citations
  5. 5DDDR-36. Tirabrutinib Therapy for Refractory or Relapsed Primary Central Nervous System Lymphoma: A Retrospective Analysis of 13 Cases2025